Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 121–144 of 151
Lancôme and Timeline have partnered to develop a skincare line using urolithin A (Mitopure), a molecule that enhances mitochondrial function in skin cells to address aging at the cellular level rather than merely treating visible signs. This represents a shift in luxury skincare from cosmetic coverage to supporting long-term cellular vitality and resilience.
Artificial intelligence is compressing drug discovery timelines from four to five years to approximately fourteen months by automating target identification, molecular design, and clinical trial prediction. This acceleration has direct implications for longevity therapeutics, where speed to market can determine whether interventions reach patients before age-related decline progresses beyond intervention points.
Energy Span reframes fatigue as a quantifiable, systems-level signal of healthspan decline that emerges before conventional biomarkers shift into pathological ranges. This perspective bridges the gap between subjective experience and measurable biology, positioning energy as an early warning system reflecting mitochondrial function, metabolic flexibility, circadian rhythm, and autonomic regulation operating in concert.
WHOOP has joined a $34.5 million Stanford-led research initiative to develop the first FDA-grade Intrinsic Capacity score, a predictive model designed to quantify functional healthspan and forecast major health outcomes up to 20 years in advance. The THRIVE coalition integrates continuous wearable physiological data with clinical biomarkers and functional assessments to measure resilience and detect early shifts toward vulnerability before disease manifests.
Foodhak uses AI-driven personalization to translate nutrition science into daily food guidance aligned with individual health markers and goals. The approach positions food as preventive medicine rather than caloric constraint, addressing a systemic gap where most food choices optimize for taste and cost rather than long-term health outcomes.
Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
PDE5 inhibitors, established drugs for erectile dysfunction, are attracting early interest in longevity medicine for their capacity to improve vascular function and tissue resilience through nitric oxide signaling—not by targeting root causes of aging, but by supporting system performance under the stress of accumulated damage.
WHOOP has secured $575 million in Series G funding at a $10.1 billion valuation, positioning itself as a continuous health monitoring platform that translates physiological data into actionable guidance. The funding reflects investor confidence that longevity platforms embedding real-time health tracking into daily life can shift healthcare from reactive to proactive intervention.
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
A longitudinal study found that 45% of older adults show cognitive improvement over a decade, with positive age-related beliefs associated with better outcomes. This challenges the assumption that cognitive decline is inevitable with age and suggests mindset-dependent mechanisms may influence cognitive trajectory.
Life Time is deploying SpiroFit, a cordless wearable metabolic testing system, across 190 clubs to measure VO2 max and fuel utilization during exercise. The technology generates personalized heart-rate training zones with lab-grade accuracy, enabling members to optimize training intensity and metabolic efficiency.
Perplexity has launched an AI-powered health platform that aggregates fragmented health data from medical records, wearables, and provider systems into a unified dashboard, enabling personalized health insights grounded in individual biomarkers and trends. This addresses a critical infrastructure gap in longevity practice: the ability to contextualize health signals across time and across systems, moving beyond isolated data points toward pattern recognition that supports earlier intervention.
Herbalife's acquisition of Bioniq signals market maturation toward data-driven, individually tailored supplementation based on blood biomarkers and lifestyle data. This shift reflects growing recognition that generic micronutrient approaches fail to address individual metabolic variation and optimization needs.
ARPA-H has awarded $22 million to Linnaeus Therapeutics to test LNS8801, an oral drug designed to preserve physical and cognitive function in aging before decline occurs. The approach represents a shift from treating age-related disease toward maintaining the integrated capacities that sustain independence and resilience.
Regional analysis of 450 European regions over 27 years reveals that life expectancy gains remain sustained in leading regions despite broader stagnation, indicating that longevity plateaus are regional and contextual rather than universal biological limits. Geographic disparities in longevity trajectories suggest that environmental, social, and health system factors continue to drive meaningful variation in human lifespan potential.
Eight Sleep's Pod smart mattress uses continuous biometric monitoring during sleep—tracking heart rate, heart rate variability, and breathing patterns—to shift from reactive treatment to predictive intervention. The company's $1.5 billion valuation reflects a strategic thesis that sleep represents both a high-frequency measurement window and an actionable intervention point for longevity and early disease detection.
A longitudinal study of over 11,000 adults aged 65 and older found that 45% showed improvement in cognitive and/or physical functioning over 12 years, with positive age-related beliefs predicting these gains. This challenges the pervasive assumption that chronological aging inevitably produces decline and demonstrates that improvement remains physiologically possible in later life.
